These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26212254)

  • 1. The potential of cholesteryl ester transfer protein as a therapeutic target.
    Gautier T; Masson D; Lagrost L
    Expert Opin Ther Targets; 2016; 20(1):47-59. PubMed ID: 26212254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead--Pro.
    Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):439-41. PubMed ID: 26848159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of CETP inhibitors: a patent review.
    Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
    Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances on the research of the relationship between cholesteryl ester transfer protein and atherosclerosis].
    Huang ZY; Guo HW
    Wei Sheng Yan Jiu; 2005 Nov; 34(6):765-7. PubMed ID: 16535859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
    Quintão EC
    Eur J Clin Invest; 2016 Jun; 46(6):581-9. PubMed ID: 26992444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol ester transfer protein: a therapeutic target in atherosclerosis?
    Vourvouhaki E; Dedoussis GV
    Expert Opin Ther Targets; 2008 Aug; 12(8):937-48. PubMed ID: 18620517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viability of developing CETP inhibitors.
    Sirtori CR; Mombelli G
    Cardiovasc Ther; 2008; 26(2):135-46. PubMed ID: 18485135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
    Johannsen TH; Frikke-Schmidt R; Schou J; Nordestgaard BG; Tybjærg-Hansen A
    J Am Coll Cardiol; 2012 Nov; 60(20):2041-8. PubMed ID: 23083790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CETP Inhibition in CVD Prevention: an Actual Appraisal.
    Di Bartolo B; Takata K; Duong M; Nicholls SJ
    Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
    Okamoto H; Yonemori F; Wakitani K; Minowa T; Maeda K; Shinkai H
    Nature; 2000 Jul; 406(6792):203-7. PubMed ID: 10910363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.